Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.

Saved in:
Bibliographic Details
Title: Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Authors: Correale P; Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Siena, Italy., Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Caraglia M, Gotti G, Francini G
Source: Cancer biology & therapy [Cancer Biol Ther] 2009 Mar 15; Vol. 8 (6), pp. 497-502. Date of Electronic Publication: 2009 Mar 15.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1555-8576
DOI:10.4161/cbt.8.6.7593